Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 15/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3701439 | 0.89 | PTGES (0.47) | PTGESRAF1BRAF | |
| SCHEMBL10173670 | 0.87 | PTGES (0.47) | PTGESMAPTMAPK1MEN1CYP1A2 | |
| SCHEMBL6124864 | 0.84 | PTGES (0.43) | PTGESLMNAMEN1KMT2A | |
| SCHEMBL3704799 | 0.83 | PTGES (0.41) | PTGESMAPTMAPK1MEN1KMT2A | |
| SCHEMBL16364060 | 0.83 | PTGES (0.48) | PTGES | |
| SCHEMBL1972512 | 0.82 | EPHX2 (0.50) | — | |
| SCHEMBL3706721 | 0.82 | PTGES (0.46) | PTGESRAF1BRAF | |
| SCHEMBL6124867 | 0.81 | PTGES (0.42) | PTGESMEN1KMT2A | |
| SCHEMBL2364015 | 0.81 | PTGES (0.42) | PTGESMAPK1MEN1CYP1A2CYP2D6 | |
| SCHEMBL3702852 | 0.81 | PTGES (0.41) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | claimed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-9040565-B2 | 1H-benzimidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2010034797-A1 | 1H-BENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122930-A1 | 1H-Benzimidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, MAP4 | PTGES 179/4885RAF1 1572/4885BRAF 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.